Kesler Norman & Wride LLC Decreases Stock Holdings in Zoetis Inc. (NYSE:ZTS)

Kesler Norman & Wride LLC lessened its stake in Zoetis Inc. (NYSE:ZTS) by 16.7% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 5,257 shares of the company’s stock after selling 1,054 shares during the period. Kesler Norman & Wride LLC’s holdings in Zoetis were worth $1,027,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also added to or reduced their stakes in the company. Price T Rowe Associates Inc. MD boosted its position in shares of Zoetis by 31.0% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 13,716,681 shares of the company’s stock worth $2,707,262,000 after purchasing an additional 3,244,074 shares in the last quarter. Global Assets Advisory LLC purchased a new stake in shares of Zoetis during the first quarter worth about $8,831,000. Franklin Street Advisors Inc. NC grew its stake in shares of Zoetis by 4.3% during the first quarter. Franklin Street Advisors Inc. NC now owns 121,024 shares of the company’s stock worth $20,478,000 after acquiring an additional 5,035 shares during the last quarter. Prevail Innovative Wealth Advisors LLC grew its stake in shares of Zoetis by 24.5% during the first quarter. Prevail Innovative Wealth Advisors LLC now owns 18,977 shares of the company’s stock worth $3,211,000 after acquiring an additional 3,738 shares during the last quarter. Finally, Jacobi Capital Management LLC grew its stake in shares of Zoetis by 10.9% during the fourth quarter. Jacobi Capital Management LLC now owns 8,040 shares of the company’s stock worth $1,587,000 after acquiring an additional 788 shares during the last quarter. 92.80% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on ZTS shares. Stifel Nicolaus boosted their price target on Zoetis from $200.00 to $210.00 and gave the stock a “buy” rating in a research note on Wednesday, September 18th. BTIG Research upped their target price on Zoetis from $220.00 to $225.00 and gave the company a “buy” rating in a research report on Monday, August 12th. Argus upgraded Zoetis to a “strong-buy” rating in a research report on Friday, August 9th. Finally, Piper Sandler upped their price objective on Zoetis from $195.00 to $210.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 14th. Nine investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Buy” and an average price target of $220.38.

Zoetis Stock Down 1.4 %

NYSE ZTS opened at $187.28 on Tuesday. The business has a fifty day moving average price of $187.30 and a 200 day moving average price of $175.50. Zoetis Inc. has a one year low of $144.80 and a one year high of $201.92. The company has a debt-to-equity ratio of 1.32, a quick ratio of 2.09 and a current ratio of 3.45. The company has a market cap of $84.85 billion, a P/E ratio of 36.08, a P/E/G ratio of 2.91 and a beta of 0.89.

Zoetis (NYSE:ZTS) last posted its quarterly earnings data on Tuesday, August 6th. The company reported $1.56 EPS for the quarter, beating the consensus estimate of $1.49 by $0.07. Zoetis had a return on equity of 50.67% and a net margin of 26.29%. The firm had revenue of $2.36 billion during the quarter, compared to the consensus estimate of $2.31 billion. During the same period in the prior year, the company earned $1.41 EPS. The firm’s revenue was up 8.3% compared to the same quarter last year. Research analysts anticipate that Zoetis Inc. will post 5.84 EPS for the current fiscal year.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.